DrugPatentWatch Database Preview
SEYSARA Drug Profile
When do Seysara patents expire, and what generic alternatives are available?
Seysara is a drug marketed by Almirall and is included in one NDA. There are four patents protecting this drug.
This drug has forty-two patent family members in fifteen countries.
The generic ingredient in SEYSARA is sarecycline hydrochloride. One supplier is listed for this compound. Additional details are available on the sarecycline hydrochloride profile page.
Summary for SEYSARA
| International Patents: | 42 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for SEYSARA |
| DailyMed Link: | SEYSARA at DailyMed |
Generic Entry Opportunity Date for SEYSARA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for SEYSARA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Almirall | SEYSARA | sarecycline hydrochloride | TABLET;ORAL | 209521-001 | Oct 1, 2018 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Almirall | SEYSARA | sarecycline hydrochloride | TABLET;ORAL | 209521-003 | Oct 1, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Almirall | SEYSARA | sarecycline hydrochloride | TABLET;ORAL | 209521-002 | Oct 1, 2018 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Almirall | SEYSARA | sarecycline hydrochloride | TABLET;ORAL | 209521-001 | Oct 1, 2018 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Almirall | SEYSARA | sarecycline hydrochloride | TABLET;ORAL | 209521-002 | Oct 1, 2018 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
